<DOC>
	<DOCNO>NCT00651911</DOCNO>
	<brief_summary>An open-label study determine efficacy safety Rasburicase use prevention treatment tumor lysis syndrome</brief_summary>
	<brief_title>Fasturtec TLS Treatment / Prophylysis</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Tumor Lysis Syndrome</mesh_term>
	<mesh_term>Rasburicase</mesh_term>
	<criteria>Chemotherapy plan least 3 cycle Undergoing cytoreductive chemotherapy ALL , multiple myeloma Burkitt 's lymphoma stage III IV With minimum life expectancy 3 month Uric acid &gt; 8 mg % Negative pregnancy test &lt; =to 2 week efficient contraceptive method . Negative HIV serology &lt; =to 4 week Patient legal guardian sign write informed consent Hypersensitivity uricases excipients Known history G6PD deficiency . Previous treatment Rasburicase UricozymeÂ® Pregnancy lactation Treatment investigational drug within 30 day plan first Rasburicase administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>